Continuous Bioprocessing Platforms

Just - Evotec Biologics has developed and  proven an integrated continuous biomanufacturing platform. It combines a perfusion cell culture step with a fully connected and intensified downstream process. We manufacture drug substance with hybrid (‘semi-continuous’) or fully continuous (‘end-to-end’) modes of operation using either 500 L or 1000 L scale single-use bioreactors depending on the amount of drug substance needed.

Our continuous bioprocess platform is designed to produce monoclonal antibody, bispecific antibody, biosimilars, and next-generation biologics.

Our continuous manufacturing approach is extremely flexible while capable of delivering the high mass outputs more commonly associated with traditional large-scale stainless-steel fed-batch facilities. We have high expressing cell lines and integrated single-use upstream and downstream processing unit operations to maximize process intensification. Our innovative control strategy is enabled by our proprietary automation.

Just – Evotec Biologics scientists are experienced in process development for continuous biomanufacturing. We perform process development for biopharmaceuticals in pre- and early-phase clinical development. Our expertise extends to converting existing fed-batch processes to our continuous biomanufacturing platform in preparation for commercial launch.

Within our continuous bioprocess platform, an intensified perfusion cell culture process results in high and consistent viable cell densities. Our process controls and process analytical technologies ensure the cell culture is held in a ‘steady state’ resulting in greater product consistency.

Perfusion cell culture allows cells to be maintained in a healthier state than in fed-batch manufacturing and reduces the leakage of intracellular contents, such as proteases, that degrade biological products. In this way, perfusion cell cultures are capable of delivering the highest biopharmaceutical product quality.

Drug substance manufacturing throughput is ramped up to meet product demand simply by extending the perfusion time and increasing the number of downstream cycles. We have proven that, in this way, we can significantly increase productivity compared to traditional fed batch processes.

Our fully end-to-end continuous bioprocessing strategy can deliver titers of 4 g/L/day or more and can reduce COGs for a monoclonal antibody by as much as 75% for a commercial product¹. 

We are committed to achieving COGs below US$ 50 per gram, as part of our mission to dramatically expand access to biotherapeutics.

_{1) Garcia F.A & Gefroh E., Drug Discovery Today (2023)}